SYNCHRONIZE-1 Through an Endocrinologist's Lens: Weight Loss Quality, Visceral Fat, and Liver Fat Reduction

In this episode, 'SYNCHRONIZE-1 Through an Endocrinologist's Lens: Weight Loss Quality, Visceral Fat, and Liver Fat Reduction,' Jaime Almandoz, MD explores the following questions:

The SYNCHRONIZE-1 trial demonstrated up to 16.6% mean weight loss and up to 63.1% reduction in liver fat after 76 weeks. As an endocrinologist managing patients at the intersection of obesity, metabolic dysfunction, and liver disease, how do you interpret these findings?

The sub-study data showed up to 34% reduction in visceral fat after 76 weeks. How might this reduction in visceral fat change how you think about this class relative to other weight loss pharmacotherapies you use today?

Almandoz described his interpretation of the SYNCHRONIZE-1 findings, noting that while substantial and statistically significant weight reduction was observed, what captured his attention most was the nature and distribution of that weight loss, with the MRI sub-study demonstrating meaningful reductions in visceral and liver fat alongside relative preservation of lean mass, collectively pointing to a quality of weight loss that is biologically distinct from generalized weight loss. He also highlighted that the concept of weight loss quality is increasingly important to both clinicians and patients, explaining that visceral and ectopic fat are the specific adipose depots most strongly linked to insulin resistance, cardiometabolic risk, and progression of liver disease, making a 34% reduction in visceral fat not just a metabolic marker but a signal that the therapy is meaningfully disrupting the biological drivers of disease. Almandoz further emphasized that the visceral fat findings reinforce the importance of measuring beyond BMI in clinical practice, advocating for routine waist circumference and waist-to-height ratio assessments to better identify patients with elevated visceral adiposity who are at high cardiometabolic risk, and expressing hope that health systems will increasingly incorporate these anthropometric measures into their standard tracking frameworks for at-risk metabolic patients.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the final episode, 'The Cost of Waiting: An Endocrinologist's Economic Case for Earlier Metabolic Disease Intervention,' Jaime Almandoz will share his closing reflections on the economic argument for treating obesity and its downstream consequences, including MASH, at earlier stages of disease, and what data payers and employers should be tracking to understand the true long-term value of earlier, more aggressive metabolic intervention.